These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12166500)

  • 1. Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis.
    Chabot S; Yong FP; Le DM; Metz LM; Myles T; Yong VW
    Mult Scler; 2002 Aug; 8(4):299-306. PubMed ID: 12166500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
    Duda PW; Schmied MC; Cook SL; Krieger JI; Hafler DA
    J Clin Invest; 2000 Apr; 105(7):967-76. PubMed ID: 10749576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of copolymer-1-activated T cells and microglia in retinal ganglion cell protection.
    Qian S; Tang Y; Cheng L; Sun X; Tian J; Zhou C
    Clin Exp Ophthalmol; 2013 Dec; 41(9):881-90. PubMed ID: 23566072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ.
    Aharoni R; Kayhan B; Eilam R; Sela M; Arnon R
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14157-62. PubMed ID: 14614135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action.
    Farina C; Weber MS; Meinl E; Wekerle H; Hohlfeld R
    Lancet Neurol; 2005 Sep; 4(9):567-75. PubMed ID: 16109363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.
    Lalive PH; Neuhaus O; Benkhoucha M; Burger D; Hohlfeld R; Zamvil SS; Weber MS
    CNS Drugs; 2011 May; 25(5):401-14. PubMed ID: 21476611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis.
    Kim HJ; Ifergan I; Antel JP; Seguin R; Duddy M; Lapierre Y; Jalili F; Bar-Or A
    J Immunol; 2004 Jun; 172(11):7144-53. PubMed ID: 15153538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients.
    Qin Y; Zhang DQ; Prat A; Pouly S; Antel J
    J Neuroimmunol; 2000 Aug; 108(1-2):201-6. PubMed ID: 10900354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple sclerosis: modulation of apoptosis susceptibility by glatiramer acetate.
    Aktas O; Ari N; Rieks M; Hoffmann V; Schimrigk S; Przuntek H; Pöhlau D
    Acta Neurol Scand; 2001 Nov; 104(5):266-70. PubMed ID: 11696019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glatiramer acetate (Copaxone) therapy for multiple sclerosis.
    Dhib-Jalbut S
    Pharmacol Ther; 2003 May; 98(2):245-55. PubMed ID: 12725872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma.
    Li Q; Milo R; Panitch H; Swoveland P; Bever CT
    Eur J Pharmacol; 1998 Jan; 342(2-3):303-10. PubMed ID: 9548401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glatiramer acetate: mechanisms of action in multiple sclerosis.
    Schrempf W; Ziemssen T
    Autoimmun Rev; 2007 Aug; 6(7):469-75. PubMed ID: 17643935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS.
    Chen M; Gran B; Costello K; Johnson K; Martin R; Dhib-Jalbut S
    Mult Scler; 2001 Aug; 7(4):209-19. PubMed ID: 11548979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells.
    Ragheb S; Abramczyk S; Lisak D; Lisak R
    Mult Scler; 2001 Feb; 7(1):43-7. PubMed ID: 11321193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate.
    Arnon R; Aharoni R
    J Neural Transm (Vienna); 2009 Nov; 116(11):1443-9. PubMed ID: 19669693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent insights into the mechanism of action of glatiramer acetate.
    Kala M; Miravalle A; Vollmer T
    J Neuroimmunol; 2011 Jun; 235(1-2):9-17. PubMed ID: 21402415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications.
    Arnon R; Aharoni R
    Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14593-8. PubMed ID: 15371592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glatiramer Acetate administration does not reduce damage after cerebral ischemia in mice.
    Poittevin M; Deroide N; Azibani F; Delcayre C; Giannesini C; Levy BI; Pocard M; Kubis N
    J Neuroimmunol; 2013 Jan; 254(1-2):55-62. PubMed ID: 23026222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory effects of glatiramer acetate on superantigen- and mitogen-induced T-cell stimulation in vitro.
    Schmidt S; Balzer S; Nüllen C; Schmidt M; Pohl C; von Rücker A; Klockgether T
    Mult Scler; 2002 Aug; 8(4):307-9. PubMed ID: 12166501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity.
    Stüve O; Youssef S; Weber MS; Nessler S; von Büdingen HC; Hemmer B; Prod'homme T; Sobel RA; Steinman L; Zamvil SS
    J Clin Invest; 2006 Apr; 116(4):1037-44. PubMed ID: 16543951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.